U.S. Oncology Based Molecular Diagnostics Market Size Worth USD 2.29 Billion by 2034 | CAGR: 5.5%

The U.S. oncology based molecular diagnostics market size is expected to reach USD 2.29 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. Oncology Based Molecular Diagnostics Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Reagents, Others), By Technology, By Type – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The field of oncology-based molecular diagnostics focuses on analyzing the genetic and molecular makeup of a cancer patient. It involves various tests that study DNA, RNA, and proteins to find specific genetic mutations, gene expressions, and other biomarkers linked to a tumor. This information helps doctors better understand the disease, choose the most effective and targeted therapies, and monitor patient’s response to the treatment. These tests are a key part of the move toward personalized medicine, as they enable a deeper, more tailored approach to cancer care.

The U.S. oncology based molecular diagnostics market is experiencing strong growth due to the rising number of cancer cases and the increasing adoption of precision medicine. The market growth is also being fueled by ongoing technological advancements, particularly in areas such as next-generation sequencing and liquid biopsy, which make diagnostics faster and less invasive. There is also a greater focus on government and private investments in cancer research, which is leading to the development of new diagnostic tools. Overall, the market is expanding as these technologies become more integrated into routine clinical practice, helping to improve cancer diagnosis and patient outcomes.

Have Questions? Request a sample or make an inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/us-oncology-based-molecular-diagnostics-market/request-for-sample

U.S. Oncology Based Molecular Diagnostics Market Report Highlights:

• By product, the reagents segment held the largest share in the market in 2024 due to its nature as a consumable product. They are essential for performing diagnostic tests, which creates a constant and recurring demand that is directly tied to the overall volume of testing.
• By technology, the polymerase chain reaction (PCR) segment held the largest share in 2024. Its widespread use is a result of it being a well-established, reliable, and cost-effective method that is commonly used in clinical labs for various diagnostic procedures.
• By type, the breast cancer segment held the largest share in 2024 due to the high number of breast cancer cases and a strong emphasis on early detection and screening. Molecular diagnostics play a critical role in treatment planning for this type of cancer by helping to identify key biomarkers.
• A few key players in the market include Roche Diagnostics, Thermo Fisher Scientific, QIAGEN, Illumina, Abbott, Agilent Technologies, Danaher, Hologic, Myriad Genetics, and Sysmex.

Polaris Market Research has segmented the U.S. oncology based molecular diagnostics market report based on product, technology, and type:

By Product Outlook (Revenue – USD Billion, 2020–2034)

• Instruments
• Reagents
• Others

By Technology Outlook (Revenue – USD Billion, 2020–2034)

• PCR
• In situ hybridization
• INAAT
• Sequencing
• Others

By Type Outlook (Revenue – USD Billion, 2020–2034)

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Cervical Cancer
• Liver Cancer
• Lung Cancer
• Blood Cancer
• Kidney Cancer
• Others